{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:08:34Z","timestamp":1777590514813,"version":"3.51.4"},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.2169\/internalmedicine.1266-18","type":"journal-article","created":{"date-parts":[[2018,11,18]],"date-time":"2018-11-18T17:33:08Z","timestamp":1542562388000},"page":"707-712","source":"Crossref","is-referenced-by-count":4,"title":["Successful Bridging Chemotherapy with Gemcitabine, Carboplatin, and Dexamethasone before Unrelated Stem Cell Transplantation for Hepatosplenic T-cell Lymphoma"],"prefix":"10.2169","volume":"58","author":[{"given":"Marika","family":"Okuni","sequence":"first","affiliation":[{"name":"The Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimikazu","family":"Yakushijin","sequence":"additional","affiliation":[{"name":"The Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Uehara","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Kobe University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"The Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Suto","sequence":"additional","affiliation":[{"name":"The Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Clinical Immunology, Kobe City Nishi-Kobe Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Clinical Immunology, Kobe City Nishi-Kobe Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaku","family":"Shinzato","sequence":"additional","affiliation":[{"name":"Department of Hematology and Clinical Immunology, Kobe City Nishi-Kobe Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Sakai","sequence":"additional","affiliation":[{"name":"The Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Mizutani","sequence":"additional","affiliation":[{"name":"The Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Nagao","sequence":"additional","affiliation":[{"name":"The Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Kurata","sequence":"additional","affiliation":[{"name":"The Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Kakiuchi","sequence":"additional","affiliation":[{"name":"The Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiharu","family":"Miyata","sequence":"additional","affiliation":[{"name":"The Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Inui","sequence":"additional","affiliation":[{"name":"The Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Molecular and Cellular Signaling, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Kawamoto","sequence":"additional","affiliation":[{"name":"The Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"The Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Ito","sequence":"additional","affiliation":[{"name":"Laboratory of Hematology, Division of Medical Biophysics, Kobe University Graduate School of Health Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"The Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[{"name":"The Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26: 4124-4130, 2008.","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Durani U, Go RS. Incidence, clinical findings, and survival of hepatosplenic T-cell lymphoma in the United States. Am J Hematol 92: E99-E101, 2017.","DOI":"10.1002\/ajh.24711"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yabe M, Medeiros LJ, Tang G, et al. Prognostic factors of hepatosplenic T-cell lymphoma: clinicopathologic study of 28 cases. Am J Surg Pathol 40: 676-688, 2016.","DOI":"10.1097\/PAS.0000000000000614"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Visnyei K, Grossbard ML, Shapira I. Hepatosplenic gammadelta T-cell lymphoma: an overview. Clin Lymphoma Myeloma Leuk 13: 360-369, 2013.","DOI":"10.1016\/j.clml.2013.03.011"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Rashidi A, Cashen AF. Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma. Blood Cancer J 5: e318, 2015.","DOI":"10.1038\/bcj.2015.43"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Gopal AK, Press OW, Shustov AR, et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed\/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma 51: 1523-1529, 2010.","DOI":"10.3109\/10428194.2010.491137"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 102: 4261-4269, 2003.","DOI":"10.1182\/blood-2003-05-1675"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Falchook GS, Vega F, Dang NH, et al. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 20: 1080-1085, 2009.","DOI":"10.1093\/annonc\/mdn751"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tanase A, Schmitz N, Stein H, et al. Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party. Leukemia 29: 686-688, 2015.","DOI":"10.1038\/leu.2014.280"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Cappella P, Tomasoni D, Faretta M, et al. Cell cycle effects of gemcitabine. Int J Cancer 93: 401-408, 2001.","DOI":"10.1002\/ijc.1351"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 21: 860-863, 2010.","DOI":"10.1093\/annonc\/mdp508"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Dong M, He XH, Liu P, et al. Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma. Med Oncol 30: 351, 2013.","DOI":"10.1007\/s12032-012-0351-4"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/5\/58_1266-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T00:36:11Z","timestamp":1551486971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/5\/58_1266-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1266-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]}}}